Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 5, Issue 3, Pages 465-476Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.5.3.465
Keywords
apoptosis; bortezomib; combination therapies; multiple myeloma; proteasome; PS-341
Categories
Funding
- PHS HHS [P01 78378, R01-50947] Funding Source: Medline
Ask authors/readers for more resources
The ubiquitin-proteasome pathway is a principal intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies since several cell cycle regulators and modulators of apoptosis are degraded through this pathway. The current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the US Food and Drug Administration for the treatment of advanced multiple myeloma, is reviewed. Particular emphasis is placed on the preclinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and an appraisal of possible uses in other hematologic malignancies, such as non-Hodgkin's lymphomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available